Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
- Interventions
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT03635489
- Locations
- 🇨🇳
the First Hospital of Jilin University, Changchun, China
🇨🇳Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing City, China
🇨🇳Tianjin Medical University General Hospital, Tianjin, China
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 173
- Registration Number
- NCT03629184
- Locations
- 🇺🇸
The Probe Medical Research, Los Angeles, California, United States
🇺🇸Kentucky Pediatric Research Center, Bardstown, Kentucky, United States
🇺🇸Orange County Research Institute, Ontario, California, United States
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
- Conditions
- Metastatic Melanoma
- Interventions
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT03625141
- Locations
- 🇧🇷
Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil
🇧🇷Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda, Ijui, RS, Brazil
🇧🇷Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
- Conditions
- Diabetic Macular Edema
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 940
- Registration Number
- NCT03622580
- Locations
- 🇺🇸
Orange County Retina Med Group, Santa Ana, California, United States
🇺🇸Kaiser Permanente Riverside Medical Center, Riverside, California, United States
🇺🇸Cumberland Valley Retina PC, Hagerstown, Maryland, United States
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema
- Conditions
- Diabetic Macular Edema
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 951
- Registration Number
- NCT03622593
- Locations
- 🇨🇦
Toronto Retina Institute, Toronto, Ontario, Canada
🇨🇦Unity Health Toronto, Toronto, Ontario, Canada
🇺🇸Retina Consultants of Nevada, Las Vegas, Nevada, United States
A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)
- Conditions
- Autism Spectrum Disorder
- Interventions
- Other: No Intervention
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 144
- Registration Number
- NCT03611075
- Locations
- 🇺🇸
PCSD Feighner Research, San Diego, California, United States
🇺🇸Southwest Autism Research and Resource Center, Phoenix, Arizona, United States
🇺🇸Harmonex Neuroscience Research, Dothan, Alabama, United States
This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1500
- Registration Number
- NCT03599245
- Locations
- 🇦🇷
Centro de Especialidades Neurológicas y Rehabilitación - CENyR, Buenos Aires, Argentina
🇧🇷Instituto de Neurologia de Curitiba, Curitiba, PR, Brazil
🇧🇪UZ Antwerpen, Edegem, Belgium
Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT03596632
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc, Madison, Wisconsin, United States
Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1710
- Registration Number
- NCT03593590
- Locations
- 🇧🇪
Revalidatie en MS Centrum, Overpelt, Belgium
🇧🇬Multiprofile Hosp. for Active Treatment;National Cardiology Hosp., Sofia, Bulgaria
🇧🇬"City Clinic UMHAC" EOOD, Sofia, Bulgaria
A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Ocrelizumab 300 mgDrug: Ocrelizumab 600 mg
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 423
- Registration Number
- NCT03589105
- Locations
- 🇫🇷
CHU de la Timone - Hopital d Adultes; Service de Neurologie, Marseille, France
🇫🇷Fondation Hopital Saint Joseph; Neurologie, Marseille, France
🇫🇷Centre hospitalier Annecy Genevois Site St Julien; Neurologie, Metz Tessy, France